Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 July, 2018 03:55 IST
Zydus Cadila gets USFDAs final nod for Phentermine HCl tablets
Source: IRIS | 30 Jun, 2017, 10.10AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Phentermine Hydrochloride Orally Disintegrating Tablets in strengths of 15 mg, 30 mg, and 37.5 mg.

The drug is used together with diet and exercise to treat obesity (overweight) in people with risk factors such as high blood pressure, high cholesterol or diabetes and will be produced at the group’s formulations manufacturing facility at Moraiya in Ahmedabad.

Shares of the company gained Rs 3.55, or 0.68%, to trade at Rs 525.45. The total volume of shares traded was 16,403 at the BSE (10.03 a.m., Friday).





Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Tata Power launches electric vehicle charging stations in Hyderabad - 18-Jul-2018 15:45
Kridhan Infra VNC's JV bags order worth Rs 2.22 bn - 18-Jul-2018 12:38
Sun Pharma gets USFDA approval of INFUGEM injection - 18-Jul-2018 12:02
Zydus receives four consecutive ANDA approvals from USFDA - 18-Jul-2018 10:55
Zee Entertainment Enterprises quarterly earnings up 31% - 17-Jul-2018 15:53
NBCC receives Rs 4 bn order from Govt of India - 17-Jul-2018 12:21
Zydus Cadila gets approval for Clindamycin Phosphate topical solution - 17-Jul-2018 11:08
Fitch affirms Indian Oil Corporation at 'BBB-'; outlook stable - 17-Jul-2018 10:31
Temporary trading halt on MCX on July 16, 2018 - 17-Jul-2018 10:25
SSWL gets 18,000 wheels order from European after market - 17-Jul-2018 10:20
Larsen & Tubro arm secures onshore EPC contract from HPCL-Mittal Energy - 17-Jul-2018 10:08
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer